Adenosine Prospect Medical in Limba Engleza
Adenosine Prospect Medical in Limba Engleza
Adenosine Prospect Medical in Limba Engleza
Intravenous infusion: The investigation should be carried out by a physician with the
necessary specialist knowledge and with equipment for acute cardiac care within reach.
To avoid possible bolus effects, the infusion should be given in a separate intravenous
line.
Blood pressure should be measured on the opposite arm of that with the adenosine
infusion.
Dosage. Treatment of paroxysmal supraventricular tachycardia, PSVT.
Adults: Initially 5 mg is given as a rapid intravenous injection over 1-2 seconds followed
by flushing with physiological saline (approximately 5 ml). If necessary, a further dose of
10 mg (followed by a saline flush) may be administered after 1-2 minutes. If the required
result is still not obtained, the dose may be increased once again until AV-block is
achieved. Treatment may be repeated twice at 1-2 min intervals. Doses greater than 15
mg are usually not required.
Infants, children and adolescents: Treatment should be carried out under specialized
conditions. Cardio-respiratory resuscitation equipment must be available for immediate
use if necessary. Adenosine is intended for use with continuous ECG monitoring during
administration.
Overdose
Adenosin Life Medical should be used only in clinics where there is careful monitoring
of patients so that overdosage in the normal meaning of the word does not take place.
However, severe symptoms associated with side-effects can be treated with
aminophylline if reduction of the dose of Adenosin Life Medical does not help. Clinical
experience has shown that aminophylline treatment is rarely required.
Incompatibilities
Adenosin Life Medical must not be mixed with other medicinal product.
Shelf-life
Unopened packs: 5 years.
After opening or following reconstitution: For immediate and single use only.
Special precautions for disposal
Can be mixed with 0.9% NaCl solution.
The solution should be inspected visually for particulate matter and discoloration prior
to administration. Do not use if cloudiness or precipitate is observed. If crystallisation
has occurred, dissolve crystals by warming at room temperature. The solution must be
clear at the time of use.
From a microbiological point of view, the product should be used immediately after
opening.
If not used immediately, in-use storage times and conditions prior to use are the
responsibility of the user.
Any unused product or waste material should be disposed of in accordance with local
requirements.
Life Medical Sweden AB
Brahegatan 29
SE-114 37 Stockholm
Sweden